Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma

被引:3
|
作者
Zganjar, Andrew [1 ]
Khanna, Abhinav [1 ]
Joyce, Dan [1 ]
Nichols, Paige [1 ]
Britton, Cameron [1 ]
Lohse, Christine M. [2 ]
Cheville, John C. [3 ]
Gupta, Sounak [3 ]
Potretzke, Aaron M. [1 ]
Thompson, R. Houston [1 ]
Leibovich, Bradley C. [1 ]
Boorjian, Stephen A. [1 ]
Sharma, Vidit [1 ]
机构
[1] Mayo Clin, Dept Urol, 200 First St SW, Rochester, MN 55901 USA
[2] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
来源
JOURNAL OF UROLOGY | 2024年 / 212卷 / 02期
关键词
kidney neoplasms; nephrectomy; renal cell carcinoma; POSTOPERATIVE PROGNOSTIC NOMOGRAM; ADJUVANT PEMBROLIZUMAB; RADICAL NEPHRECTOMY; PREDICTION; MANAGEMENT; RECURRENCE;
D O I
10.1097/JU.0000000000004030
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The AUA guidelines introduced a new risk group stratification system based primarily on tumor stage and grade to guide surveillance for patients treated surgically for localized renal cell carcinoma (RCC). We sought to evaluate the predictive ability of these risk groups using progression-free survival (PFS) and cancer-specific survival (CSS), and to compare their performance to that of our published institutional risk models. Materials and Methods: We queried our Nephrectomy Registry to identify adults treated with radical or partial nephrectomy for unilateral, M0, clear cell RCC, or papillary RCC from 1980 to 2012. The AUA stratification does not apply to other RCC subtypes as tumor grading for other RCC, such as chromophobe, is not routinely performed. PFS and CSS were estimated using the Kaplan-Meier method. Predictive abilities were evaluated using C indexes from Cox proportional hazards regression models. Results: A total of 3191 patients with clear cell RCC and 633 patients with papillary RCC were included. For patients with clear cell RCC, C indexes for the AUA risk groups and our model were 0.780 and 0.815, respectively (P < .001) for PFS, and 0.811 and 0.857, respectively (P < .001), for CSS. For patients with papillary RCC, C indexes for the AUA risk groups and our model were 0.775 and 0.751, respectively (P = .002) for PFS, and 0.830 and 0.803, respectively (P = .2) for CSS. Conclusions: The AUA stratification is a parsimonious system for categorizing RCC that provides C indexes of about 0.80 for PFS and CSS following surgery for localized clear cell and papillary RCC.
引用
收藏
页码:331 / 341
页数:11
相关论文
共 50 条
  • [1] Letter: Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma
    Longoni, Mattia
    Rosiello, Giuseppe
    Larcher, Alessandro
    Montorsi, Francesco
    Capitanio, Umberto
    JOURNAL OF UROLOGY, 2024, 212 (04):
  • [2] Reply: Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma
    Sharma, Vidit
    JOURNAL OF UROLOGY, 2024, 212 (04): : 621 - 622
  • [3] MAYO CLINIC VALIDATION OF THE AMERICAN UROLOGIC ASSOCIATION RISK GROUPS FOR LOCALIZED RENAL CANCER
    Zganjar, Andrew
    Khanna, Abhinav
    Joyce, Dan
    Nichols, Paige
    Lohse, Christine
    Cheville, John
    Gupta, Sounak
    Potretzke, Aaron
    Thompson, R. Houston
    Leibovich, Bradley
    Boorjian, Stephen
    Sharma, Vidit
    JOURNAL OF UROLOGY, 2022, 207 (05): : E809 - E810
  • [4] External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma
    Fujii, Yasuhisa
    Saito, Kazutaka
    Iimura, Yasumasa
    Sakai, Yasuyuki
    Koga, Fumitaka
    Kawakami, Satoru
    Kumagai, Jiro
    Kihara, Kazunori
    JOURNAL OF UROLOGY, 2008, 180 (04): : 1290 - 1295
  • [5] Outcomes of patients with sarcomatoid renal cell carcinoma: The Mayo Clinic experience
    Costello, Brian Addis
    Zhang, Ben
    Lohse, Christine M.
    Boorjian, Stephen A.
    Cheville, John
    Leibovich, Bradley C.
    Thompson, Robert Houston
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma - Editorial comment
    Pavlovich, Christian P.
    JOURNAL OF UROLOGY, 2008, 180 (04): : 1295 - 1296
  • [7] EXTERNAL VALIDATION OF THE MAYO CLINIC STAGE, SIZE, GRADE, AND NECROSIS SCORE IN PATIENTS WITH RENAL CELL CARCINOMA AND VENOUS TUMOR THROMBUS
    Lorentz, Adam
    Tai, Caroline
    Capitanio, Umberto
    Carballido, Joaquin
    Ciancio, Gaetano
    Daneshmand, Siamak
    Evans, Christopher
    Gontero, Paolo
    Haferkamp, Axel
    Hohenfellner, Markus
    Huang, William
    Linares Espinos, Estefania
    Martinez-Salamanca, Juan
    McKiernan, James
    Montorsi, Francesco
    Pahernik, Sascha
    Palou, Juan
    Pruthi, Raj
    Russo, Paul
    Scherr, Douglas
    Spahn, Martin
    Terrone, Carlo
    Tilki, Derya
    Vera-Donoso, Cesar
    Vergho, Daniel
    Wallen, Eric
    Zigeuner, Richard
    Libertino, John
    Master, Viraj
    JOURNAL OF UROLOGY, 2017, 197 (04): : E66 - E67
  • [8] THE 'LEIBOVICH' - MAYO CLINIC SCORING ALGORITHM FOR CLEAR CELL RENAL CELL CARCINOMA SUPPLEMENTED BY VASCULAR INVASION
    Chromecki, T.
    Hutterer, G. C.
    Imamovic, A.
    Kampel-Kettner, K.
    Rehak, P.
    Langner, C.
    Pummer, K.
    Zigeuner, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 154 - 154
  • [9] Validation of novel grading schemes and refinement of the Leibovich risk groups for chromophobe renal cell carcinoma
    Haiyue Lin
    Caiying Wang
    Yun Zhao
    Run Wang
    Wei Xi
    Ying Xiong
    Li Xiao
    Yi Liu
    Shaoting Zhang
    Chenchen Dai
    World Journal of Urology, 43 (1)
  • [10] External validation of the Mayo clinic ssign score to predict cancer-specific survival using a European series of conventional renal cell carcinoma
    Ficarra, V
    Lohse, CM
    Novara, G
    Galfano, A
    Cavalleri, S
    Martignoni, G
    Artibani, W
    JOURNAL OF UROLOGY, 2006, 175 (04): : 357 - 358